ArticleFrontiers in endocrinology2023
Short-term use of CGM in youth onset type 2 diabetes is associated with behavioral modifications.
Article in Frontiers in endocrinology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.
- Continuous glucose monitoring in type 2 diabetes: a systematic review of barriers and opportunities for care improvement.International journal for quality in health care : journal of the International Society for Quality in Health Care · 2025Pooled it
- International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024 Diabetes Technologies: Glucose Monitoring.Hormone research in paediatrics · 2024Guideline
- ISPAD Clinical Practice Consensus Guidelines 2024: Type 2 Diabetes in Children and Adolescents.Hormone research in paediatrics · 2024Guideline
- Piloting a Postdischarge Virtual Glucose Monitoring Program for Patients With Diabetic Foot Wound in a Safety-Net Health System.Journal of diabetes science and technology · 2026Article
- Psychological Aspects and Implications of Food Addiction and Glucose Control in Type 2 Diabetes: A Pilot Mixed-Methods Study.Healthcare (Basel, Switzerland) · 2026Article
- 7. Diabetes Technology: Standards of Care in Diabetes-2026.Diabetes care · 2026Review
- Article
- The effect of education in obese type 2 diabetes adolescents and young adults based on continuous glucose monitoring and smartwatch-derived lifelog data.Annals of pediatric endocrinology & metabolism · 2025Article
- The cost-effectiveness of real-time continuous glucose monitoring versus intermittently scanned continuous glucose monitoring in individuals with insulin-treated Type 2 diabetes mellitus in Canada.Journal of comparative effectiveness research · 2025Article
- Continuous glucose monitoring in non-insulin-dependent type-2 diabetes - rationale for CGM-NIDDM study.Diabetology & metabolic syndrome · 2025Review
- 7. Diabetes Technology: Standards of Care in Diabetes-2025.Diabetes care · 2025Review
- Continuous Glucose Monitoring (CGM) as a Behavior Modification Tool: A Case Series on CGM-Guided Nutrition in People With Type 2 Diabetes Not Using Insulin.Clinical diabetes : a publication of the American Diabetes Association · 2025Article
- Are treatment options used for adult-onset type 2 diabetes mellitus (equally) available and effective for children and adolescents?World journal of diabetes · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Continuous glucose monitoring (CGM) is beneficial to glycemic control in youth with type 1 diabetes (T1D) and adults with type 2 diabetes (T2D); however, studies in youth with T2D are limited. Objective: Determine if 10-day trial CGM use in youth with T2D improves glycemic control and behavioral modifications. Methods: Youth with T2D > 3 months, on insulin, with no prior CGM use were enrolled. Staff placed CGM and provided education. Participants received 5-day and 10-day follow-up phone calls to review CGM data, behavioral modifications, and adjust insulin doses as needed. We compared 5-day to 10-day TIR, and baseline to 3-6 month HbA1c via paired t-test. Results: Participants (n=41) had median age of 16.2 y, were 61% female, 81% NH Black, median diabetes duration of 0.8 y, and baseline HbA1c of 10.3%. A majority had household income<$50,000 (81%) and parental education level of HS or less (73%). Average 5-day TIR 49% was similar to 10-day TIR 51% (p=0.62). There was no change in HbA1c after 3-6 months (10.2% v 10.3%, p=0.89). Nineteen participants completed full 10-day CGM use; of those, 84% wanted a CGM long-term. Adolescents reported behavioral changes including increased blood sugar checks, increased insulin administration and overall improved diabetes management. Conclusion: Although 10-day CGM use did not impact short-term or long-term glycemic control in youth with T2D, most participants reported behavioral changes and wanted to continue using CGM. Future studies with longer use of CGM may clarify the potential impact of CGM in youth with T2D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.